Full metadata record

DC Field Value Language
dc.contributor.authorKim, Kyoung-Ran-
dc.contributor.authorHwang, Dohyeon-
dc.contributor.authorKim, Juhyeon-
dc.contributor.authorLee, Chang-Yong-
dc.contributor.authorLee, Wonseok-
dc.contributor.authorYoon, Dae Sung-
dc.contributor.authorShin, Dongyun-
dc.contributor.authorMin, Sun-Joon-
dc.contributor.authorKwon, Ick Chan-
dc.contributor.authorChung, Hak Suk-
dc.contributor.authorAhn, Dae-Ro-
dc.date.accessioned2024-01-19T22:31:45Z-
dc.date.available2024-01-19T22:31:45Z-
dc.date.created2021-09-03-
dc.date.issued2018-06-28-
dc.identifier.issn0168-3659-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/121235-
dc.description.abstractDespite the extremely high substrate specificity and catalytically amplified activity of enzymes, the lack of efficient cellular internalization limits their application as therapeutics. To overcome this limitation and to harness enzymes as practical biologics for targeting intracellular functions, we developed the streptavidin-mirror DNA tetrahedron hybrid as a platform for intracellular delivery of various enzymes. The hybrid consists of streptavidin, which provides a stoichiometrically controlled loading site for the enzyme cargo and an L-DNA (mirror DNA) tetrahedron, which provides the intracellular delivery potential. Due to the cell-penetrating ability of the mirror DNA tetrahedron of this hybrid, enzymes loaded on streptavidin can be efficiently delivered into the cells, intracellularly expressing their activity. In addition, we demonstrate tumor delivery of enzymes in an animal model by utilizing the potential of the hybrid to accumulate in tumors. Strikingly, the hybrid is able to transfer the apoptotic enzyme specifically into tumor cells, leading to strong suppression of tumor growth without causing significant damage to other tissues. These results suggest that the hybrid may allow anti-proliferative enzymes and proteins to be utilized as anticancer drugs.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectARGININE-DEPENDENT CANCERS-
dc.subjectMAMMALIAN-CELLS-
dc.subjectL-ASPARAGINASE-
dc.subjectIN-VITRO-
dc.subjectPROTEIN-
dc.subjectTHERAPY-
dc.subjectSYSTEM-
dc.subjectDRUG-
dc.subjectNANOPARTICLES-
dc.subjectDEIMINASE-
dc.titleStreptavidin-mirror DNA tetrahedron hybrid as a platform for intracellular and tumor delivery of enzymes-
dc.typeArticle-
dc.identifier.doi10.1016/j.jconrel.2018.04.051-
dc.description.journalClass1-
dc.identifier.bibliographicCitationJOURNAL OF CONTROLLED RELEASE, v.280, pp.1 - 10-
dc.citation.titleJOURNAL OF CONTROLLED RELEASE-
dc.citation.volume280-
dc.citation.startPage1-
dc.citation.endPage10-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000434382100001-
dc.identifier.scopusid2-s2.0-85046513813-
dc.relation.journalWebOfScienceCategoryChemistry, Multidisciplinary-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaChemistry-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusARGININE-DEPENDENT CANCERS-
dc.subject.keywordPlusMAMMALIAN-CELLS-
dc.subject.keywordPlusL-ASPARAGINASE-
dc.subject.keywordPlusIN-VITRO-
dc.subject.keywordPlusPROTEIN-
dc.subject.keywordPlusTHERAPY-
dc.subject.keywordPlusSYSTEM-
dc.subject.keywordPlusDRUG-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusDEIMINASE-
dc.subject.keywordAuthorEnzyme delivery-
dc.subject.keywordAuthorCancer therapy-
dc.subject.keywordAuthorDNA tetrahedron-
dc.subject.keywordAuthorStreptavidin-mirror DNA tetrahedron hybrid-
Appears in Collections:
KIST Article > 2018
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE